(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Extraordinary Snowboarding Objections All over the Planet- Embracing Practical Living and Ecological Protection
- Instructions to Augment the Presentation of Your Kona SUV
- Knesset sets special panel to fast-track Karhi’s communications reform
- Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- Make your choice for the PS5 game that you love playing with companions!
- Vote in favor of your #1 Sort of Convenience for a Family
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
